Healthcare Technology
-
What Is Gene Therapy? How It Differs from Gene Editing and Why the Distinction Matters
Gene therapy and gene editing are two of the most transformative — and most frequently confused — technologies in modern biotechnology. Both operate at the level of DNA and both aim to treat disease by addressing its genetic roots. But they work in fundamentally different ways, and that difference has important implications for which diseases…
-
What Is an Antibody-Drug Conjugate (ADC)? The Precision Oncology Technology Reshaping Cancer Treatment
Antibody-drug conjugates — universally known in biotech as ADCs — have become one of the most commercially successful and scientifically active areas of oncology drug development. With multiple blockbuster ADCs on the market and billions in pharmaceutical deal-making driven by ADC pipeline acquisitions, understanding what ADC technology is, how it works, and why the pharmaceutical…
-
What Is mRNA Technology? Beyond COVID Vaccines and Into the Future of Medicine
The COVID-19 pandemic brought mRNA technology from the laboratory into global consciousness, delivering two of the most rapidly developed and widely administered vaccines in history. But for biotech investors, the real significance of the mRNA platform is not what it accomplished in 2020 and 2021 — it is what it enables going forward. Moderna, BioNTech,…
-
What Is CAR-T Cell Therapy? Engineered Immune Cells and Their Biotech Investment Implications
CAR-T cell therapy represents one of the most significant advances in cancer treatment in decades — and one of the most technically complex, logistically challenging, and expensive therapeutic approaches ever brought to market. For biotech investors, CAR-T is both an established commercial reality and an active area of development where the next generation of therapies…
-
What Is AI in Drug Discovery? How Machine Learning Is Reshaping Biotech
Artificial intelligence has become one of the most discussed and most misunderstood concepts in the biotech sector. Some companies claim AI will compress the 15-year drug discovery timeline to a few years. Skeptics argue that AI-designed drugs are only as good as the biology they are trained on, and that the hard part of drug…
-
What Is CRISPR? Gene Editing Technology and Its Biotech Investment Implications
In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for developing CRISPR-Cas9 — a gene editing technology that has been described as one of the most significant scientific advances of the twenty-first century. For biotech investors, CRISPR is not just a scientific concept; it is a foundational platform technology that…